What is Lifesci Capital's Forecast for DNTH Q2 Earnings?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, June 18th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per share of ($0.86) for the quarter. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Lifesci Capital also issued estimates for Dianthus Therapeutics' Q3 2025 earnings at ($0.87) EPS and Q4 2025 earnings at ($0.89) EPS.

Several other equities research analysts also recently weighed in on DNTH. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Robert W. Baird cut their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $0.21 during mid-day trading on Monday, hitting $18.13. 149,848 shares of the stock traded hands, compared to its average volume of 274,694. Dianthus Therapeutics has a twelve month low of $13.37 and a twelve month high of $32.27. The company has a market cap of $583.06 million, a PE ratio of -6.30 and a beta of 1.36. The firm has a 50 day simple moving average of $19.16 and a two-hundred day simple moving average of $20.70.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock worth $1,972,000 after buying an additional 55,682 shares during the period. Northern Trust Corp increased its holdings in Dianthus Therapeutics by 21.2% during the 4th quarter. Northern Trust Corp now owns 245,523 shares of the company's stock worth $5,352,000 after purchasing an additional 42,923 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after purchasing an additional 136,633 shares in the last quarter. Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after purchasing an additional 680,000 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after acquiring an additional 36,133 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.